Company Profile
Harmony Biosciences Stock Price, News & Analysis
Company overview
Business overview
Harmony Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Harmony Biosciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Harmony Biosciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Harmony Biosciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
HRMY is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Harmony Biosciences's catalysts are Wakix execution, sleep-franchise expansion, and any CNS update that widens the portfolio. The stock moves when the core sleep business keeps growing with discipline.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Source: Harmony Biosciences
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.